Ciprofloxacin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ciprofloxacin

Examples of brand names: Ciprobay [DE]

ATC code: J01MA02

Main use (for orientation): Bacterial infections

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Ciprofloxacin. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Concomitant medicines and exposure are confounders; do not assume all fluoroquinolones have the same mechanisms. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Renal elimination, CYP1A2 inhibition and drug-specific CNS/QT risks.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: No isolated cannabinoid-related change in concentrations or events established.

Context: A warfarin case involving multiple substances, alcohol and cannabis does not establish ciprofloxacin–cannabinoid causality.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0293]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Renal elimination, CYP1A2 inhibition and drug-specific CNS/QT risks.

Source: CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.] [V2_LABEL_D0293]

Source role [CA_P_42666628]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: A warfarin case involving multiple substances, alcohol and cannabis does not establish ciprofloxacin–cannabinoid causality.

Source: Delayed Traumatic Subarachnoid Hemorrhage Following Initially Negative Computed Tomography (CT) Imaging in a Patient With a Mechanical Mitral Valve and Markedly Elevated International Normalized Ratio (INR). [CA_P_42666628]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Concomitant medicines and exposure are confounders; do not assume all fluoroquinolones have the same mechanisms.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0293] CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: PD-Rx Pharmaceuticals, Inc.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_42666628] Delayed Traumatic Subarachnoid Hemorrhage Following Initially Negative Computed Tomography (CT) Imaging in a Patient With a Mechanical Mitral Valve and Markedly Elevated International Normalized Ratio (INR).

Original source / bibliographic reference

Authors: Sauers KN, Tomlinson PL, Hall TE.

Year: 2026

Source type: Journal Article; Case Reports; case-report

DOI: 10.7759/cureus.113580

PMID: 42666628

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility